CN104056056B - A kind of Chinese medicine oral liquid treating leukopenia after chemotherapy - Google Patents
A kind of Chinese medicine oral liquid treating leukopenia after chemotherapy Download PDFInfo
- Publication number
- CN104056056B CN104056056B CN201410345228.4A CN201410345228A CN104056056B CN 104056056 B CN104056056 B CN 104056056B CN 201410345228 A CN201410345228 A CN 201410345228A CN 104056056 B CN104056056 B CN 104056056B
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- chemotherapy
- ethanol
- material medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 26
- 239000007788 liquid Substances 0.000 title claims abstract description 19
- 201000002364 leukopenia Diseases 0.000 title claims abstract description 14
- 231100001022 leukopenia Toxicity 0.000 title claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000463 material Substances 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 15
- 240000001830 Zornia reticulata Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000012467 final product Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 24
- 210000000265 Leukocytes Anatomy 0.000 abstract description 8
- 210000003734 Kidney Anatomy 0.000 abstract description 7
- 210000000952 Spleen Anatomy 0.000 abstract description 7
- 230000001225 therapeutic Effects 0.000 abstract description 6
- 231100000614 Poison Toxicity 0.000 abstract description 5
- 239000003440 toxic substance Substances 0.000 abstract description 5
- 206010065553 Bone marrow failure Diseases 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 230000000240 adjuvant Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 210000004369 Blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000012535 impurity Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 239000003390 Chinese drug Substances 0.000 description 4
- 210000004027 cells Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 206010023232 Joint swelling Diseases 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- 206010052769 Vertigos Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 231100000889 vertigo Toxicity 0.000 description 3
- XDBMTQVSHNQIFU-UHFFFAOYSA-N 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1NC(C(O)=O)CS1 XDBMTQVSHNQIFU-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 229960003513 BATILOL Drugs 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 210000001624 Hip Anatomy 0.000 description 2
- 210000003127 Knee Anatomy 0.000 description 2
- 241000608867 Leucogenes Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003203 everyday Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000388 leucogen Effects 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 229940121657 Clinical Drug Drugs 0.000 description 1
- 229940047120 Colony stimulating factors Drugs 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000002173 Dizziness Diseases 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N LSD Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 229950002454 Lysergide Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N Pidotimod Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010072736 Rheumatic disease Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001914 calming Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000610 leukopenic Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000505 pernicious Effects 0.000 description 1
- CCHNOBQMQBSRHQ-UHFFFAOYSA-N phosphoric acid;7H-purin-6-amine Chemical compound OP(O)(O)=O.NC1=NC=NC2=C1NC=N2 CCHNOBQMQBSRHQ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000025627 positive regulation of urine volume Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000000552 rheumatic Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002087 whitening Effects 0.000 description 1
Abstract
nullThe present invention relates to treat the Chinese medicine oral liquid of leukopenia after chemotherapy，Effectively solve medication during leukopenia after therapeutic treatment，Prevent induction from infecting，Curative effect is unstable，Dangerous and problem costly，It is made up of the material medicine of following parts by weight meter: the Rhizoma Atractylodis Macrocephalae 10 30 parts、Poria 12 25 parts、Rhizoma Polygonati 10 50 parts、10 30 parts of Fructus Mori、Herba Ecliptae 10 20 parts、Fructus Ligustri Lucidi 10 20 parts、Radix Fissistigmatis Glaucescentis 6 15 parts、Herba Selaginellae Doederleinii 10 25 parts、Herba Sarcandrae 6 15 parts and Zornia diphylla (Linn.) Pers. 10 30 parts，Above-mentioned raw materials medicament mixed，Add water or ethanol，Decoct 2 times，Merge 2 decoction liquor，Filter，Obtain，The present invention has strengthening spleen, tonifying kidney、Eliminating toxic substances to remove stasis，Increase effect of leukocyte，In terms of improving chemotherapy body bone marrow depression，Curative effect is certainly，It it is the innovation on the medicine of adjuvant for chemotherapy of tumour.
Description
Technical field
The present invention relates to field of medicaments, a kind of Chinese medicine oral liquid treating leukopenia after chemotherapy.
Background technology
Tumor is one of disease that threat in the present age mankind are the most serious.Operation, radiotherapy and chemotherapy are the three of clinical treatment tumours
Item Main Means, wherein chemotherapy kills residual tumor cells in the patient, can improve curative effect, improve prognosis.But cancer therapy drug lacks
Weary special selectivity, while killing cancerous cell, also can kill normal cell, the particularly bone marrow hematogenesis to molecular marker for increased proliferation
Carbazole alkaloid is even more serious, and leukopenia is complication common after Chemotherapy in Malignant Carcinoma Patients.Its side effect often making
Treat and delay or be forced to interrupt.
At present doctor trained in Western medicine prevents and treats the bone marrow depression that chemotherapy causes typically low dose of hormonotherapy；Take vitamin, batilol,
Leucogen's therapy；The most repeatedly leukocyte conveying or whole blood conveying；Use granulocyte colony-stimulating factor etc..But these treatments
Method or have and easily induce infection, or uncertain therapeutic efficacy is cut, or expense is too high, and most of patients is difficult to shortcomings such as bearing.Therefore, protection bone
Marrow, leukocyte increasing become a problem in chemotherapy of tumors, and in this regard, Chinese medicine has irreplaceable, unique excellent
Gesture.
Summary of the invention
For above-mentioned situation, for overcoming prior art defect, the purpose of the present invention is just to provide after one treats chemotherapy white
The Chinese medicine oral liquid of cytopenia, can effectively solve medication during leukopenia after therapeutic treatment, prevents induction from infecting,
Curative effect is unstable, dangerous and problem costly.
The technical scheme that the present invention solves is to be made up of the material medicine of following parts by weight meter: Rhizoma Atractylodis Macrocephalae 10-30 part,
Poria 12-25 part, Rhizoma Polygonati 10-50 part, Fructus Mori 10-30 part, Herba Ecliptae 10-20 part, Fructus Ligustri Lucidi 10-20 part, Radix Fissistigmatis Glaucescentis 6-15
Part, Herba Selaginellae Doederleinii 10-25 part, Herba Sarcandrae 6-15 part and Zornia diphylla (Linn.) Pers. 10-30 part, wherein, by above-mentioned raw materials medicament mixed together, often
The secondary water adding 4-6 times of weight of material medicine or volumetric concentration are the ethanol of 70%, decoct 2 times, each 70 minutes, decoct for the first time
Time, first by water or soak with ethanol 1 hour, merge 2 decoction liquor, filter, to obtain final product.
When Chinese medicine oral liquid of the present invention also can be concentrated into 60 DEG C, relative density is the fluid extract of 1.14-1.18, uses routine
Method is respectively prepared the tablet of adjuvant therapy treatment, granule, capsule, pill, the dosage form of syrup any one application.
The present invention has strengthening spleen, tonifying kidney, eliminating toxic substances to remove stasis, increases effect of leukocyte, is improving chemotherapy body bone marrow depression side
Face, curative effect certainly, is the innovation on the medicine of adjuvant for chemotherapy of tumour.
Detailed description of the invention
Below in conjunction with embodiment, the detailed description of the invention of the present invention is described in further detail.
Embodiment 1
In the specific implementation, oral liquid of the present invention also can be made up of the material medicine of following parts by weight meter: the Rhizoma Atractylodis Macrocephalae 10 parts,
Poria 12 parts, Rhizoma Polygonati 10 parts, 10 parts of Fructus Mori, Herba Ecliptae 10 parts, Fructus Ligustri Lucidi 10 parts, Radix Fissistigmatis Glaucescentis 6 parts, Herba Selaginellae Doederleinii 10 parts, swollen joint
Wind 6 parts and Zornia diphylla (Linn.) Pers. 10 parts, wherein, by above-mentioned raw materials medicament mixed together, add water or the body of 4 times of weight of material medicine every time
Volume concentrations is the ethanol of 70%, decocts 2 times, each 70 minutes, when decocting for the first time, first by water or soak with ethanol 1 hour, merges
2 decoction liquor, filter, to obtain final product.
Embodiment 2
In the specific implementation, oral liquid of the present invention also can be made up of the material medicine of following parts by weight meter: the Rhizoma Atractylodis Macrocephalae 20 parts,
Poria 18 parts, Rhizoma Polygonati 30 parts, 20 parts of Fructus Mori, Herba Ecliptae 15 parts, Fructus Ligustri Lucidi 15 parts, Radix Fissistigmatis Glaucescentis 10 parts, Herba Selaginellae Doederleinii 18 parts, swollen joint
Wind 10 parts and Zornia diphylla (Linn.) Pers. 20 parts, wherein, by above-mentioned raw materials medicament mixed together, add every time 5 times of weight of material medicine water or
Volumetric concentration is the ethanol of 70%, decocts 2 times, each 70 minutes, when decocting for the first time, first by water or soak with ethanol 1 hour, closes
And 2 decoction liquor, filter, to obtain final product.
Embodiment 3
In the specific implementation, oral liquid of the present invention also can be made up of the material medicine of following parts by weight meter: the Rhizoma Atractylodis Macrocephalae 30 parts,
Poria 25 parts, Rhizoma Polygonati 50 parts, 30 parts of Fructus Mori, Herba Ecliptae 20 parts, Fructus Ligustri Lucidi 20 parts, Radix Fissistigmatis Glaucescentis 15 parts, Herba Selaginellae Doederleinii 25 parts, swollen joint
Wind 15 parts and Zornia diphylla (Linn.) Pers. 30 parts, wherein, by above-mentioned raw materials medicament mixed together, add every time 6 times of weight of material medicine water or
Volumetric concentration is the ethanol of 70%, decocts 2 times, each 70 minutes, when decocting for the first time, first by water or soak with ethanol 1 hour, closes
And 2 decoction liquor, filter, to obtain final product.
Embodiment 4
In the specific implementation, oral liquid of the present invention is made up of the material medicine of following parts by weight meter: the Rhizoma Atractylodis Macrocephalae 15 parts, white
20 parts of Poria, Rhizoma Polygonati 10 parts, 10 parts of Fructus Mori, Herba Ecliptae 10 parts, Fructus Ligustri Lucidi 15 parts, Radix Fissistigmatis Glaucescentis 15 parts, Herba Selaginellae Doederleinii 25 parts, Herba Sarcandrae
15 parts and Zornia diphylla (Linn.) Pers. 20 parts, wherein, by above-mentioned raw materials medicament mixed together, add the water of 4 times of weight of material medicine every time, decocts
2 times, each 70 minutes, when decocting for the first time, first it is soaked in water 1 hour, merges 2 decoction liquor, filter, to obtain final product.
Embodiment 5
In the specific implementation, oral liquid of the present invention is made up of the material medicine of following parts by weight meter: the Rhizoma Atractylodis Macrocephalae 25 parts, white
12 parts of Poria, Rhizoma Polygonati 40 parts, 25 parts of Fructus Mori, Herba Ecliptae 15 parts, Fructus Ligustri Lucidi 10 parts, Radix Fissistigmatis Glaucescentis 6 parts, Herba Selaginellae Doederleinii 10 parts, Herba Sarcandrae 6
Part and Zornia diphylla (Linn.) Pers. 15 parts, wherein, by above-mentioned raw materials medicament mixed together, add the volumetric concentration of 5 times of weight of material medicine every time
It is the ethanol of 70%, decocts 2 times, each 70 minutes, when decocting for the first time, first use soak with ethanol 1 hour, merge 2 decoction liquor,
Filter, to obtain final product.
The foregoing is only the optimal case study on implementation of the present invention, be merely illustrative for the purpose of the present invention, and unrestricted
Property, those skilled in the art understand, in the scope of the claims in the present invention can to its carry out some equivalent or etc.
The replacement of effect or replacement, but its essence is identical, broadly falls into protection scope of the present invention.
The above medicine, wherein:
The Rhizoma Atractylodis Macrocephalae: remove impurity, cleans, runs through, cut sheet, is dried, has invigorating the spleen and benefiting QI, and effect of dampness diuretic, for spleen
Empty lack of appetite, abdominal distention has loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration.
Poria: take Poria and soak, clean, slightly steam after profit, crust of pruning in time, cutting in bulk or cut sheet, dries, has
Promoting diuresis to eliminate damp pathogen, spleen invigorating, effect of mind calming.
Rhizoma Polygonati: remove impurity, cleans, slightly moistens, cut sheet, is dried, has boosting qi and nourishing yin, spleen invigorating, lung moistening, effect of kidney tonifying.
Fructus Mori: clean, dry, YIN nourishing of enriching blood, effect moisturized of promoting the production of body fluid.For vertigo and tinnitus, palpitation and insomnia, beard and hair is early
In vain, Tianjin wound is thirsty, and interior-heat is quenched one's thirst.
Herba Ecliptae: remove impurity, slightly wash, cutting, is dried, has nourishing the liver and kidney, and effect of cooling blood for hemostasis is cloudy for Liver and kidney
Void, odontoseisis, early whitening of beard and hair, vertigo and tinnitus, soreness of the waist and knees, YinXuXueRe.
Fructus Ligustri Lucidi: removing impurity, cleaning, drying, have nourishing the liver and kidney, effect of improving eyesight black hair, for the hepatic and renal YIN deficiency, dizziness
Ear toot, soreness of the waist and knees, beard and hair drought is white, poor vision, and interior-heat is quenched one's thirst, osteopyrexia and fever.
Radix Fissistigmatis Glaucescentis: remove fibrous root, cleans, dries, have wind-damp dispelling, the effect restore menstrual flow and invigorate blood circulation, stopped blooding.
The effects such as Herba Selaginellae Doederleinii: clean, dry, has heat-clearing and toxic substances removing, expelling wind and removing dampness, stop blooding, anticancer.
Herba Sarcandrae: remove impurity, cleans, runs through, cutting, is dried, has clearing away heat and cooling blood, speckle removing of invigorating blood circulation, the merit of dispelling wind and removing obstruction in the collateral
Effect.Speckle dermexanthesis, rheumatic arthralgia is sent out for heat in blood.
Zornia diphylla (Linn.) Pers.: remove impurity, cleans, dries, have heat-clearing and toxic substances removing, removing blood stasis to reduce swelling, adjusted effect of dampness removing.
From said medicine, the present invention all medicines phase 5, there is strengthening spleen, tonifying kidney, effect of eliminating toxic substances to remove stasis, can be effectively used for
The treatment of leukopenia after chemotherapy, curative effect certainly, and by clinic application, achieves good effect, relevant testing data
As follows:
One, zoopery
1 materials and methods
1.1 animals and packet cleaning grade male ICR mouse 60, body weight 18-22g.
1.2 medicines and instrument cyclophosphamide (CTX), cellanalyzer, Olympus biological microscope, cytometry
Plate.
1.3 modeling
By S180 ascites tumor mice milky ascites, with normal saline dilution to 2 × 106Individual/mL and viable count are more than
95%, it is inoculated in the right axil of mice with 0.2mL subcutaneous, tests in inoculated tumour cell second day.
1.4 method
Mice 60 is only randomly divided into 4 groups, it may be assumed that 1, Normal group (0.2m l/10g normal saline), and 2, model group
(80mg/kg CTX), 3, positive controls (0.03mg/kg recombinant human granulocyte colony stimulating factor), 4, Chinese drug-treated group of the present invention
(25g/kg).Totally 14 days experimental period.Normal group, Chinese drug-treated group gastric infusion every day of the present invention 1 time, totally 14 days；Experiment the
8-10 days, except Normal group, remaining each group lumbar injection CTX80mg/kg, every day 1 time；Positive controls mice is in 11-
13 days subcutaneous injection recombinant human granulocyte colony stimulating factors.
1.5 testing index peripheral white blood cells and frangments smear (BMNC)
1.6 statistical analysis
Experimental result all withRepresent, use SPSS15.0 statistical package to carry out statistical analysis.Use Dan Yin
Element variance analysis (ANOVA), compares between group two-by-two, uses the inspection of LSD method, and P ＜ 0.05 has significance for difference.
2 results
Comparing with Normal group, model control group WBC, BMNC quantity significantly reduce (P ＜ 0.01)；With model control group
Relatively, Chinese drug-treated group WBC of the present invention, BMNC digital display write and raise (P ＜ 0.05)；Compare between positive controls and Chinese drug-treated group of the present invention
Relatively, no significant difference (P ＞ 0.05).
Table 1 respectively organize mouse peripheral blood as and the comparison of frangments smear
* P ＜ 0.05 * * P ＜ 0.05 is compared with model group
Two, clinical trial data of the present invention is as follows:
1, data and method
1.1 clinical datas:
All patients underwent operative or proved by pathology are malignant tumor.Hepatic and renal function is looked into normal, without blood system disease before chemotherapy
Disease, WBC ＞ 4.0 × 109/ more than L, all cases all use standard chemotherapy regimen [Wang Huaqing, Cui Xiuzhen, Wan Ling, etc. pernicious
Chemotherapy of tumors scheme specification [M] Shenyang: Liaoning Science Press, 2002:14], double inspection WBC counting in chemotherapy process
＜ 4.0 × 109/L.All cases is randomly divided into treatment group 40 example, matched group 41 example.Two groups of sexes, age, diseases are planted and leukocyte
Minimizing degree (severe: WBC counting≤2.0 × 109/ L, moderate: WBC counting≤3.0 × 109/ L, slight: WBC counting≤4.0 ×
109/ L) etc. data compare through statistics, there was no significant difference (P ＞ 0.05), there is comparability, be specifically shown in Table 2.
Table 2 treatment group and matched group clinic physical data compare
1.2 therapeutic scheme
Treatment group: Chinese medicine oral liquid of the present invention, the most once, each 200ml；Matched group: leucogen 20mg, 1d3 time；
Adenine phosphate 20mg, 1d3 time；Batilol 50mg, 1d3 time；The most oral；Two groups was all a course for the treatment of with two weeks.
1.3 criterion of therapeutical effect
With reference to drug for increasing white cells curative effect in " clinical drug research guideline " that Ministry of Health of the People's Republic of China formulates
Standard.Effective: continuous 2 numeration of leukocyte in 1 week > 4.0 × 109/ L, and 1 week can be maintained；Effective: in 1 week continuous 2 times white thin
Born of the same parents' counting improves 100% earlier above, or rises to 3.0 × 109/ L, and 1 week can be maintained；Invalid: numeration of leukocyte is without substantially increasing.
1.4 therapeutic outcome
Treatment group 40 example, effective 16 examples, effective 22 examples, invalid 2 examples, total effective rate 95%；Matched group 41 example, effective 10
Example, effective 23 examples, invalid 8 examples, total effective rate 80.5%.
1.5 conclusion
By above-mentioned it should be apparent that Chinese medicine oral liquid of the present invention is better than matched group, and during medication, do not find
Having any harmful effect, drug safety, curative effect is affirmed, up to 95%, and low cost, easily it is accepted by patients, swollen after solving chemotherapy
Generally there is bone marrow depression, leukopenic problem in tumor patient, is effective to the application in adjuvant for chemotherapy of tumour medicine, has
Actual clinical meaning.
Claims (6)
1. the Chinese medicine oral liquid treating leukopenia after chemotherapy, it is characterised in that by following parts by weight meter
Material medicine is made: Rhizoma Atractylodis Macrocephalae 10-30 part, Poria 12-25 part, Rhizoma Polygonati 10-50 part, Fructus Mori 10-30 part, Herba Ecliptae 10-20 part,
Fructus Ligustri Lucidi 10-20 part, Radix Fissistigmatis Glaucescentis 6-15 part, Herba Selaginellae Doederleinii 10-25 part, Herba Sarcandrae 6-15 part and Zornia diphylla (Linn.) Pers. 10-30 part, wherein, will
Together, the water or the volumetric concentration that add 4-6 times of weight of material medicine are the ethanol of 70% to above-mentioned raw materials medicament mixed every time, decoct 2
Secondary, each 70 minutes, when decocting for the first time, first by water or soak with ethanol 1 hour, merges 2 decoction liquor, filtration, to obtain final product.
The Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy the most according to claim 1, it is characterised in that by following
The material medicine of parts by weight meter is made: the Rhizoma Atractylodis Macrocephalae 10 parts, Poria 12 parts, Rhizoma Polygonati 10 parts, 10 parts of Fructus Mori, Herba Ecliptae 10 parts, female
Loyal son 10 parts, Radix Fissistigmatis Glaucescentis 6 parts, Herba Selaginellae Doederleinii 10 parts, Herba Sarcandrae 6 parts and Zornia diphylla (Linn.) Pers. 10 parts, wherein, exist above-mentioned raw materials medicament mixed
Together, the water or the volumetric concentration that add 4 times of weight of material medicine are the ethanol of 70% every time, decoct 2 times, each 70 minutes, for the first time
During decoction, first by water or soak with ethanol 1 hour, merge 2 decoction liquor, filter, to obtain final product.
The Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy the most according to claim 1, it is characterised in that by following
The material medicine of parts by weight meter is made: the Rhizoma Atractylodis Macrocephalae 20 parts, Poria 18 parts, Rhizoma Polygonati 30 parts, 20 parts of Fructus Mori, Herba Ecliptae 15 parts, female
Loyal son 15 parts, Radix Fissistigmatis Glaucescentis 10 parts, Herba Selaginellae Doederleinii 18 parts, Herba Sarcandrae 10 parts and Zornia diphylla (Linn.) Pers. 20 parts, wherein, by above-mentioned raw materials medicament mixed
Together, the water or the volumetric concentration that add 5 times of weight of material medicine are the ethanol of 70% every time, decoct 2 times, each 70 minutes, first
Secondary when decocting, first by water or soak with ethanol 1 hour, merges 2 decoction liquor, filtration, to obtain final product.
The Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy the most according to claim 1, it is characterised in that by following
The material medicine of parts by weight meter is made: the Rhizoma Atractylodis Macrocephalae 30 parts, Poria 25 parts, Rhizoma Polygonati 50 parts, 30 parts of Fructus Mori, Herba Ecliptae 20 parts, female
Loyal son 20 parts, Radix Fissistigmatis Glaucescentis 15 parts, Herba Selaginellae Doederleinii 25 parts, Herba Sarcandrae 15 parts and Zornia diphylla (Linn.) Pers. 30 parts, wherein, by above-mentioned raw materials medicament mixed
Together, the water or the volumetric concentration that add 6 times of weight of material medicine are the ethanol of 70% every time, decoct 2 times, each 70 minutes, first
Secondary when decocting, first by water or soak with ethanol 1 hour, merges 2 decoction liquor, filtration, to obtain final product.
The Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy the most according to claim 1, it is characterised in that by following
The material medicine of parts by weight meter is made: the Rhizoma Atractylodis Macrocephalae 15 parts, Poria 20 parts, Rhizoma Polygonati 10 parts, 10 parts of Fructus Mori, Herba Ecliptae 10 parts, female
Loyal son 15 parts, Radix Fissistigmatis Glaucescentis 15 parts, Herba Selaginellae Doederleinii 25 parts, Herba Sarcandrae 15 parts and Zornia diphylla (Linn.) Pers. 20 parts, wherein, by above-mentioned raw materials medicament mixed
Together, add the water of 4 times of weight of material medicine every time, decoct 2 times, each 70 minutes, when decocting for the first time, be first soaked in water 1
Hour, merge 2 decoction liquor, filter, to obtain final product.
The Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy the most according to claim 1, it is characterised in that by following
The material medicine of parts by weight meter is made: the Rhizoma Atractylodis Macrocephalae 25 parts, Poria 12 parts, Rhizoma Polygonati 40 parts, 25 parts of Fructus Mori, Herba Ecliptae 15 parts, female
Loyal son 10 parts, Radix Fissistigmatis Glaucescentis 6 parts, Herba Selaginellae Doederleinii 10 parts, Herba Sarcandrae 6 parts and Zornia diphylla (Linn.) Pers. 15 parts, wherein, exist above-mentioned raw materials medicament mixed
Together, add the ethanol that volumetric concentration is 70% of 5 times of weight of material medicine every time, decoct 2 times, each 70 minutes, decoct for the first time
Time, first use soak with ethanol 1 hour, merge 2 decoction liquor, filter, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410345228.4A CN104056056B (en) | 2014-07-19 | A kind of Chinese medicine oral liquid treating leukopenia after chemotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410345228.4A CN104056056B (en) | 2014-07-19 | A kind of Chinese medicine oral liquid treating leukopenia after chemotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104056056A CN104056056A (en) | 2014-09-24 |
| CN104056056B true CN104056056B (en) | 2016-11-30 |
Family
ID=
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277034A (en) * | 2000-06-09 | 2000-12-20 | 中国人民解放军军事医学科学院放射医学研究所 | Chinese medicine preparation |
| CN1739676A (en) * | 2005-08-26 | 2006-03-01 | 咸阳步长医药科技发展有限公司 | Chinese medicine mixture for treating leucopenia caused by tumor treating radiation therapy and chemotherapy and its quality control method |
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277034A (en) * | 2000-06-09 | 2000-12-20 | 中国人民解放军军事医学科学院放射医学研究所 | Chinese medicine preparation |
| CN1739676A (en) * | 2005-08-26 | 2006-03-01 | 咸阳步长医药科技发展有限公司 | Chinese medicine mixture for treating leucopenia caused by tumor treating radiation therapy and chemotherapy and its quality control method |
Non-Patent Citations (2)
| Title |
|---|
| 从脾肾论治肿瘤化疗后白细胞下降的体会;董爱峰;《河南中医》;20080610;第28卷(第06期);第52页 * |
| 扶正升白汤加减治疗化疗后白细胞减少症的临床观察;李宁鸿，毛如宝，王娇阳;《中国中西医结合杂志》;19950220;第15卷(第02期);第104-105页 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014139282A1 (en) | Pharmaceutical compositions for treating cancer of genital system and preparation method therefor | |
| CN101181529B (en) | Chinese medicine composition for curing tumor and preparation method thereof | |
| CN104147534A (en) | Traditional Chinese medicine composition for treating various cancers | |
| CN106390013A (en) | Compound traditional Chinese medicine composition capable of inhibiting colorectal liver metastases as well as preparation method and application thereof | |
| CN102697903A (en) | Medicine for treating herpes zoster | |
| CN103861079A (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN105902604A (en) | Compound medicament for treating T-cell acute lymphoblastic leukemia (T-ALL) | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN1305515C (en) | Chinese medicinal powder and decoction composition for treating cancer | |
| CN102302567B (en) | Stagnation-removing and stasis-removing Chinese patent medicine | |
| CN104547502B (en) | A kind of Chinese medicine composition for treating Sjogren syndrome | |
| CN102697984B (en) | Chinese medicinal external application preparation for treating acute mastitis | |
| CN109248305A (en) | A kind of Chinese medicine composition and preparation method thereof for treating liver fibrosis | |
| CN102614424A (en) | Traditional Chinese medicine for treatment of edema | |
| CN104056056B (en) | A kind of Chinese medicine oral liquid treating leukopenia after chemotherapy | |
| CN102755515A (en) | Traditional Chinese medicine decoction for treating hyperplasia of mammary glands | |
| CN103223046B (en) | Traditional Chinese medicine for treating hyperplasia of mammary glands | |
| CN103191369B (en) | Chinese medicinal composition for treating mammary gland hyperplasia | |
| CN102266434B (en) | Chinese medicinal composition for resisting tumor metastasis and preparation method thereof | |
| CN104056056A (en) | Traditional Chinese medicine oral liquid for treating leukopenia after chemotherapy | |
| CN103961477B (en) | The endo-medicine and its preparation method of preventing and treating nursing period at initial stage acute mastitis | |
| CN108635498B (en) | Pharmaceutical composition for treating myelodysplastic syndrome and application thereof | |
| CN101979072A (en) | Chinese medicament for treating chronic liver disease | |
| CN102526431B (en) | Traditional Chinese medicine preparation for treating gastric cancer and preparation method | |
| CN101953943A (en) | Traditional Chinese medicine for treating chronic aplastic anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161130 Termination date: 20170719 |